A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

NCT ID: NCT07229599

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-09
• Study Completion Date: 2030-05-31

Brief Summary

This is a first-in-human, open-label, multicenter Phase I/II study of MHB036C combined with MHB039A or other anti-tumor therapy in patients with advanced lung cancer. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB036C combined with MHB039A or other anti-tumor therapies.

Detailed Description

This first-in-human clinical trial of MHB036C combined with MHB039A or other anti-tumor therapy comprises two parts: a dose escalation phase and dose expansion phase. The dose escalation phase is an open-label, multicenter study including dose escalation and PK expansion cohorts. The primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MHB036C combining different anti-tumor treatment regimens (including Furmonertinib, MHB039A for injection, and Carboplatin) in patients with advanced lung cancer, and to determine the maximum tolerated dose (MTD). Additional patients may be enrolled in the PK expansion part at dose levels that have completed DLT (dose-limiting toxicity) evaluation.

Based on the safety, PK, and preliminary efficacy data from the completed DLT-evaluated dose levels, the sponsor will initiate the dose expansion phase to further evaluate the safety and efficacy of MHB036C combined with MHB039A or other anti-tumor therapy in patients with specific types of advanced lung cancer.

Conditions

Advanced Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose escalation: cohort 1

Subjects will receive MHB036C Q3W by intravenous administration in combination with Furmonertinib QD by oral administration.

Group Type: EXPERIMENTAL

MHB036C for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Furmonertinib

Intervention Type: DRUG

Oral administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Dose escalation: cohort 2

Subjects will receive MHB036C Q3W in combination with MHB039A Q3W by intravenous administration

Group Type: EXPERIMENTAL

MHB036C for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

MHB039A for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Dose escalation: cohort 3

Subjects will receive MHB036C Q3W in combination with Carboplatin AUC 5mg/mL/min by intravenous administration

Group Type: EXPERIMENTAL

MHB036C for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Carboplatin

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Dose expansion: cohort 4

Subjects will receive MHB036C Q3W by intravenous administration in combination with Furmonertinib QD by oral administration.

Group Type: EXPERIMENTAL

MHB036C for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Furmonertinib

Intervention Type: DRUG

Oral administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Dose expansion: cohort 5

Subjects will receive MHB036C Q3W in combination with MHB039A Q3W by intravenous administration

Group Type: EXPERIMENTAL

MHB036C for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

MHB039A for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Dose expansion: cohort 6

Subjects will receive MHB036C Q3W in combination with Carboplatin AUC 5mg/mL/min by intravenous administration

Group Type: EXPERIMENTAL

MHB036C for Injection

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Carboplatin

Intervention Type: DRUG

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Interventions

MHB036C for Injection

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention Type: DRUG

MHB039A for Injection

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention Type: DRUG

Furmonertinib

Oral administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention Type: DRUG

Carboplatin

IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Voluntarily agrees to participate in the study and signs the informed consent form.

2. Age ≥ 18 years and≤75 years, no restriction on gender.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

4. Estimated life expectancy ≥ 3 months.

5. For the dose escalation stage: Histologically or cytologically confirmed advanced solid tumors that are refractory to standard therapy, intolerant to standard therapy, or have no standard treatment options.

6. For the dose expansion stage: Histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors, not suitable for radical surgery and/or radical concurrent/sequential radiotherapy and chemotherapy.

7. At least one measurable lesion per RECIST v1.1 criteria.

8. Adequate bone marrow reserve and organ function.

9. Eligible participants of childbearing potential (males and females) must agree to take highly reliable contraceptive measures with their partners during the study and within at least 12 weeks after the last dose.

-

Exclusion Criteria

1. Small cell lung cancer (SCLC) components in the histopathology.

2. History of ≥2 primary malignancies within 5 years prior to informed consent.

3. Received chemotherapy within 3 weeks, radiotherapy within 4 weeks, or biologic, endocrine, or immunotherapy within 4 weeks before first study dose.

4. Medication of other unmarketed investigational drugs or therapies within 4 weeks before dosing.

5. Brain metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.

6. Underwent major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first dose of investigational drug or requiring elective surgery during the study.

7. Previous or concurrent gastrointestinal perforation, surgical procedures and wound healing complications, as well as bleeding events.

8. Received intravenous thrombolysis treatment within 2 weeks, except for preventive anticoagulation and antiplatelet therapy.

9. Vaccinated within 4 weeks before dosing.

10. Treated with systemic corticosteroids within 14 days before dosing.

11. Severe impairment of pulmonary function; interstitial lung disease or a history of pneumonia requiring steroid treatment; previous left or right pneumonectomy.

12. Active systemic infection requiring treatment within 7 days before dosing.

13. Uncontrolled third-space effusion.

14. Serious cardiovascular or cerebrovascular diseases.

15. Known hypersensitivity or delayed allergic reaction to the investigational product or its components.

16. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.

17. Known alcohol or drug dependence.

18. Pregnant or breastfeeding women, or individuals planning to conceive. -

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Minghui Pharmaceutical (Hangzhou) Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

CMO/ Senior Vice President of R&D

Role: CONTACT

jwshi@minghuipharma.com

86 0571-86963293

Facility Contacts

Ethics Committee

Role: primary

chestgcp@126.com

+86 021-22200000-5341

Other Identifiers

MHB036C-A-201

Identifier Type: -

Identifier Source: org_study_id